Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,571 Mln
P/E Ratio
--
P/B Ratio
3.44
Industry P/E
--
Debt to Equity
0.17
ROE
-0.1 %
ROCE
-8.29 %
Div. Yield
0 %
Book Value
9.79
EPS
-0.95
CFO
$-124.85 Mln
EBITDA
$-333.57 Mln
Net Profit
$-234.84 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
AtriCure (ATRC)
| 7.10 | -2.42 | -17.14 | 44.12 | -17.50 | -3.82 | 4.38 |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
AtriCure (ATRC)
| -14.27 | -19.58 | -36.17 | 24.90 | 71.24 | 6.24 | 67.29 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 15.65 | 10,289.47 | 14.38 | 12.69 | |
| 72.28 | 9,544.04 | 92.52 | 2.52 | |
| 158.95 | 8,064.21 | -- | -25.23 | |
| 278.44 | 10,728.90 | 773.26 | 1.2 |
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the... Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio. Address: 7555 Innovation Way, Mason, OH, United States, 45040 Read more
CEO, President & Director
Mr. Michael H. Carrel
CEO, President & Director
Mr. Michael H. Carrel
Headquarters
Mason, OH
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of AtriCure Inc (ATRC) stood at $ 609 Mln as on 31-Dec-24
The share price of AtriCure Inc (ATRC) is $32.73 (NASDAQ) as of 23-Apr-2025 14:40 EDT. AtriCure Inc (ATRC) has given a return of -17.5% in the last 3 years.
AtriCure Inc (ATRC) has a market capitalisation of $ 1,571 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of AtriCure Inc (ATRC) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the AtriCure Inc (ATRC) and enter the required number of quantities and click on buy to purchase the shares of AtriCure Inc (ATRC).
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio. Address: 7555 Innovation Way, Mason, OH, United States, 45040
The CEO & director of Mr. Michael H. Carrel. is AtriCure Inc (ATRC), and CFO & Sr. VP is Mr. Michael H. Carrel.
There is no promoter pledging in AtriCure Inc (ATRC).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,070
|
|
|
1,049
|
|
|
978
|
|
|
820
|
| AtriCure Inc. (ATRC) | Ratios |
|---|---|
|
Return on equity(%)
|
-9.64
|
|
Operating margin(%)
|
-8.01
|
|
Net Margin(%)
|
-9.61
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of AtriCure Inc (ATRC) was $0 Mln.
$0.76
(
